SCHEMBL6307064

SCHEMBL6307064

CNc1cc(Oc2ccc3c(C(=O)NCCN4CCOCC4)cccc3c2)ncn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.58
FGFR1 P11362 3/20 0.48
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 2/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
POLB P06746 1/20 0.47
LMNA P02545 1/20 0.47
POLR1A O95602 1/20 0.46
SCN9A Q15858 1/20 0.45
CYP2C19 P33261 2/20 0.45
NPC1 O15118 1/20 0.45
CYP2C9 P11712 1/20 0.45
AURKA O14965 1/20 0.45
MET P08581 1/20 0.45
TEK Q02763 1/20 0.45
AURKB Q96GD4 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
PDGFRB P09619 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314939 0.92 KDR (0.49) KDRFGFR1ALDH1A1KDM4EHPGD
SCHEMBL5796823 0.89 KDR (0.48) KDRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL6317026 0.86 KDR (0.43) KDRFGFR1ALDH1A1KDM4EHPGD
SCHEMBL5799391 0.86 KDR (0.56) KDRFGFR1ALDH1A1KDM4EHPGD
SCHEMBL5798765 0.85 KDR (0.58) KDRFGFR1ALDH1A1KDM4EHPGD
SCHEMBL6314462 0.85 KDR (0.43) KDRFGFR1ALDH1A1KDM4EHPGD
SCHEMBL4548802 0.83 KDR (0.67) KDRAURKAMETTEKAURKB
SCHEMBL6308977 0.82 KDR (0.48) KDRFGFR1ALDH1A1KDM4EHPGD
SCHEMBL6310375 0.81 KDR (0.49) KDRFGFR1ALDH1A1KDM4EHPGD
SCHEMBL6309553 0.81 KDR (0.53) KDRFGFR1ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050070508-A1 Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents AGOURON PHARMACEUTICALS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070508-A1 Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents CCNA1, CCNA2, CCNT1 KDR 30/4885FGFR1 212/4885ALDH1A1 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.